Jounce Therapeutics — Investor Presentation (March 2022)
33 slides from Jounce Therapeutics's investor presentation, Mar 7, 2022
Slide 1: Jounce Therapeutics Corporate Presentation
Jounce Therapeutics Corporate Presentation A NEXT GEN IMMUNOTHERAPY COMPANY MARCH 2022 Exhibit 99.1
Slide 2: Legal Disclaimer
Legal Disclaimer 2 Various statements concerning our future expectations, plans and prospects, including without limitation, our expectations regarding financial guidance, operating expenses and capital expenditures, the timing, initiation, progress, results of and release of data for clinical trial
Slide 3: The Jounce Difference
Proven Management Team • Founded by IO pioneers: Nobel Coley Lasker Prize • Cash runway through Q3 2023 The Jounce Difference 3 * Out licensed to Gilead Sciences, Inc. (clinical trial sponsor) The right immunotherapy for the right patient Productive Translational Science Platform • Various immune ce
Slide 4: The Challenge and Promise of IO Therapy
The Challenge and Promise of IO Therapy Lessons Learned Define New Opportunities 4 *PD-(L)1i = PD-1 inhibitor or PD-L1 inhibitor • Tumor with PD-(L)1i* approval • Minority of pts benefit • Tumor with PD-(L)1i approval • Majority pts do not respond • Tumor with no PD-(L)1i approval • Little to no ben
Slide 5: New Immune Cell Targets Are Needed For Next Gen IO
New Immune Cell Targets Are Needed For Next Gen IO Extend benefit to more patients and realize IO market potential 5 2021 IO Market $37B* 2025 IO market $56B & growing* Next Gen IO T cell-focused • Durable benefit in minority of patients • Many tumor types unresponsive • Majority of combos are chemo
Slide 6: The Core of Our Approach: Translational Science Platform
Human Tumor Samples The Core of Our Approach: Translational Science Platform 6 *PD= Pharmacodynamic Translational Drug Discovery • Sustainable engine • Multiple immune cell types • Goal of new IND every 12 – 18 months Reverse Translational Analysis • Patients with clinical outcomes • PD* and predict
Slide 7: Jounce Immunotherapy Pipeline
DISCOVERY PROGRAMS LILRB1 (ILT2) Myeloid & Lymphoid Bi-Specifics (Not Disclosed) Diverse Immune Cell Types Other Targets (Not Disclosed) PD-(L)1i Resistance Mechanisms Jounce Immunotherapy Pipeline 7 * Formerly JTX-1811 now out-licensed to Gilead Sciences, Inc. Program Target Biology Discovery Precl
Slide 8: Lead Macrophage Program: JTX-8064
Lead Macrophage Program: JTX-8064 8
Slide 9: JTX-8064: Potential Macrophage Checkpoint Inhibitor
JTX-8064: Potential Macrophage Checkpoint Inhibitor LILRB2 / ILT4 Target • LILRB2 is expressed on immunosuppressive macrophages • Immunosuppressive macrophages are a negative prognostic factor for many cancer types • Inhibition of LILRB2 reprograms macrophages to an immune active state and activates
Slide 10: LILRB2 (ILT4) May Inhibit Response to PD-(L)1i Therapy
LILRB2 (ILT4) May Inhibit Response to PD-(L)1i Therapy 10 • CD163 is a general marker for immunosuppressive macrophages • Similar associations between OS and CD163 have been reported for most tumor types in INNATE High LILRB2 / IFNγ Signature Ratio Correlates With Poor Response to PD- (L)1i Treatmen
Slide 11: JTX-8064 Inhibits the Macrophage Checkpoint LILRB2 (ILT4)
JTX-8064 Inhibits the Macrophage Checkpoint LILRB2 (ILT4) 11 Potential to Reverse PD-(L)1i Resistance Cytokine Production Antigen Presentation T-cell Activation JTX-8064 Immunosuppressive Macrophage (M2-like) Immune Activated Macrophage (M1-like)
Slide 12: JTX-8064 Reprograms Macrophages to Enhance T Cell Responses
JTX-8064 Reprograms Macrophages to Enhance T Cell Responses 12 1. Cohen et al., Abstract 5007, AACR 2019; 2. McGrath et al., Abstract 1727, AACR 2021. JTX-8064 reprogrammed macrophages are more effective at stimulating T cells in co-culture2 Reprogramming of macrophages from M2 to an M1 state throug
Slide 13: JTX-8064: INNATE Study Design
JTX-8064: INNATE Study Designed to Rapidly Demonstrate POC Mono and Pimivalimab Combo Dose Escalation and Expansion • Full receptor occupancy at 300mg • Recommended phase 2 dose at 700mg • No Dose Limiting Toxicities (up to 1200mg) 13 7 Indication Specific Phase 2 Combo Expansion Cohorts Initiated O
Slide 14: JTX-8064: Anticipated INNATE Study Data in 2022
JTX-8064: Anticipated INNATE Study Data in 2022 Mono and Pimivalimab Combo Dose Escalation and Expansion 14 Preliminary Clinical Data in 2022 Complete mono and combo dose escalation data Safety, PK, PD, and efficacy Preliminary mono and combo expansion cohort data Data from initial portion o
Slide 15: Translational Informatics Defined Initial Tumor Types
Translational Informatics Defined Initial Tumor Types Higher Lower • Relative evaluation and ranking across all TCGA indications • Focus on 3 key RNA measures (LILRB2, Jounce TAM signature, IFNγ signature) • Figure sorted by LILRB2 15 TUMOR TYPE Testicular Cancer Mesothelioma Renal Cancer (clear cel
Slide 16: JTX-8064: INNATE Three Categories of Patients
JTX-8064: INNATE Three Categories of Patients Mechanistic potential to improve effectiveness of T cell-directed therapies 16 3/4L Ovarian Cancer (Mono & Combo) No Approved PD-(L)1i (IO Naïve Patients) 1L Head and Neck Squamous Cell Carcinoma Approved PD-1i (IO Naïve Patients) 2/3L clear cell Renal C
Slide 17: High Unmet Need in INNATE Indications
High Unmet Need in INNATE Indications * Clinical trial patients who received PD-(L)1i treatment beyond RECIST progression (PD-(L)1i as last prior therapy) References: 1 Gandara et al. Journal of Thoracic Oncology 2018; Kazandjian et al. Seminars in Oncology 2017; 2 Haddad et al. Cancer 2019; 3 Escud
Slide 18: Vopratelimab & Pimivalimab
Vopratelimab & Pimivalimab 18
Slide 19: Vopratelimab Value Proposition
Vopratelimab Value Proposition Biological Activity Distinct from CD8 Focused PD-(L)1i • Vopra is an IgG1 agonist antibody selective for ICOS (inducible co-stimulatory of T cells) • Activates CD4 T cells that have been primed by antigen presentation Key Clinical Learnings to Date • Highly durable cli
Slide 20: ICOS hi CD4 T Cells are Associated with Clinical Benefit
ICOS hi CD4 T Cells are Associated with Clinical Benefit 20 *Subset of 44 patients with evaluable blood samples and tumor measurements; based on investigator assessment Pharmacodynamic Biomarker ICONIC Trial: Overall Survival by ICOS hi CD4 Status* • Vopra treatment emergent biomarker ICOS hi CD4 T
Slide 21: TISvopra Predicts ICOS hi CD4 Cells and Clinical Benefit
TISvopra Predicts ICOS hi CD4 Cells and Clinical Benefit 21 Predictive Biomarker ICONIC Trial: Overall Survival by TISvopra Status • TISvopra predicts for on treatment emergence of ICOS hi CD4 T cells and OS Below TISvopra Cut-Off Median OS = 6.2 mo Above TISvopra Cut-Off Median OS = 16.9 mo Above B
Slide 22: SELECT: Randomized Phase Predictive Biomarker Study
SELECT: Randomized Phase 2 Predictive Biomarker Study Clinical Study of Two Wholly Owned Antibodies with New Predictive Biomarker Phase 2 SELECT Randomized POC Study • IO naïve 2L NSCLC in ~75 patients selected with TISvopra • Designed to demonstrate statistical superiority of vopra + Pimi versus Pi
Slide 23: Pimivalimab PD-1 inhibitor
Pimivalimab PD-1 inhibitor 23
Slide 24: Pimivalimab: PD-1 Inhibitor in POC Combo Studies
Pimivalimab (Pimi): PD-1 Inhibitor in 2 POC Combo Studies Well-Characterized PD-1 Antibody, Fully Human IgG4 Phase 1 Study Results* • 3/18 (16.7%) confirmed responses • No deaths or dose limiting toxicities Opportunities for Pimi • Biomarker selected IO naïve patients (SELECT) • PD-(L)1i naïve & exp
Slide 25: Discovery
Discovery 25
Slide 26: Jounce's Translational Science Platform
Jounce’s Translational Science Platform Deconstructing the Tumor Microenvironment to Identify Novel Therapeutics 26 T cell Identify targets uniquely tied to cell types of interest Profile human tumors for target expression on cell types of interest More IO Responsive Less IO Responsive Targets for l
Slide 27: JTX-1484 (Anti-LILRB4) Development Program
JTX-1484 (Anti-LILRB4) Development Program New addition to our differentiated cell type strategy 27 • Expressed on immuno-suppressive myeloid cells in the TME, including MDSCs, tolerogenic DCs and M2-like macrophages • Potent and specific blocker of human LILRB4 with favorable PK, pre-clinical safet
Slide 28: JTX-1484 (Anti-LILRB4): New Development Program
JTX-1484 (Anti-LILRB4): New Development Program 28
Slide 29: Milestones & Financials
Milestones & Financials 29
Slide 30: Upcoming Milestones
Vopratelimab (SELECT): • SELECT data 2H 2022 • Complete data from randomized study • Safety and efficacy • Performance of biomarker JTX-1484 (LILRB4): • Continue to advance towards a 2023 IND Discovery: • Continue to advance multiple new targets through discovery pipeline with a goal of an IND every
Slide 31: Financial Strength and Flexibility
Financial Strength and Flexibility NASDAQ: JNCE Strong Balance Sheet • Cash runway through Q3 2023 • Excludes any potential milestone payments • $220.2M in cash, cash equivalents and investments, as of Dec. 31, 2021 Cash Guidance • 2022 gross cash burn $115M - $130M Common Stock Outstanding • 51.3M
Slide 32: The Jounce Difference
The Jounce Difference 32 Opportunity Compelling Pipeline Upcoming Catalysts Financial Strength Clinical data expected in 2022 from both lead programs Next generation IO with discovery across a variety of different immune cell types leading to an extensive pipeline Multiple large market opportunities
Slide 33: Jounce Therapeutics
Jounce Therapeutics JOUNCETX.COM 33
Jounce Therapeutics — Investor Presentation (March 2022) on 6ix